
## **Chih-Long Chang**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9087490/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Optimal prophylactic para-aortic radiotherapy in locally advanced cervical cancer: anatomy-based versus margin-based delineation. International Journal of Gynecological Cancer, 2022, , jjgc-2021-003298.	2.5	2
2	The 6th International Workshop of the Asian Society of Gynecologic Oncology, December 19th to 20th, 2020. Journal of Gynecologic Oncology, 2021, 32, e55.	2.2	0
3	Association of bowel radiation dose-volume with skeletal muscle loss during pelvic intensity-modulated radiotherapy in cervical cancer. Supportive Care in Cancer, 2021, 29, 5497-5505.	2.2	7
4	AdvanTIG-202: A phase 2 study investigating anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab in patients with previously treated recurrent or metastatic cervical cancer Journal of Clinical Oncology, 2021, 39, TPS5595-TPS5595.	1.6	5
5	Massive metastasis of breast cancer to female genital organs. Taiwanese Journal of Obstetrics and Gynecology, 2021, 60, 563-566.	1.3	2
6	DNA methylation marker for the triage of hrHPV positive women in cervical cancer screening: Real-world evidence in Taiwan. Gynecologic Oncology, 2021, 161, 429-435.	1.4	17
7	Abstract CT154: Isatuximab (Isa) plus atezolizumab (Atezo) in patients (pts) with advanced malignancies: Results from a Phase 1/2 open-label multicenter study. , 2021, , .		1
8	Hyperthermic intraperitoneal chemotherapy enhances antitumor effects on ovarian cancer through immune-mediated cancer stem cell targeting. International Journal of Hyperthermia, 2021, 38, 1013-1022.	2.5	7
9	Immune vulnerability of ovarian cancer stem-like cells due to low CD47 expression is protected by surrounding bulk tumor cells. OncoImmunology, 2020, 9, 1803530.	4.6	13
10	Muscle Loss after Chemoradiotherapy as a Biomarker of Distant Failures in Locally Advanced Cervical Cancer. Cancers, 2020, 12, 595.	3.7	17
11	Healthy life styles, sleep and fatigue in endometrial cancer survivors: A crossâ€sectional study. Journal of Clinical Nursing, 2020, 29, 1372-1380.	3.0	6
12	Effect of Chemotherapy, Laparoscopy, and Cytology on Stage IC Ovarian Clear Cell Carcinoma: A Long-Term, Single-Center Study. International Journal of Environmental Research and Public Health, 2020, 17, 491.	2.6	9
13	Muscle loss during primary debulking surgery and chemotherapy predicts poor survival in advancedâ€ <del>s</del> tage ovarian cancer. Journal of Cachexia, Sarcopenia and Muscle, 2020, 11, 534-546.	7.3	54
14	Outcomes in Advanced Stage Epithelial Ovarian, Fallopian Tubal, and Peritoneal Cancer after Primary Surgery and Adjuvant Chemotherapies: A Single-Institute Real-World Experience. International Journal of Environmental Research and Public Health, 2020, 17, 3523.	2.6	1
15	Muscle radiodensity loss during cancer therapy is predictive for poor survival in advanced endometrial cancer. Journal of Cachexia, Sarcopenia and Muscle, 2019, 10, 814-826.	7.3	48
16	Effect of hyperthermia on improving neutrophil restoration after intraperitoneal chemotherapy. International Journal of Hyperthermia, 2019, 36, 1254-1262.	2.5	3
17	<p>Retrospective Analysis Of Comparative Outcomes In Recurrent Platinum-Sensitive Ovarian Cancer Treated With Pegylated Liposomal Doxorubicin (Lipo-Dox) And Carboplatin Versus Paclitaxel And Carboplatin</p> . Cancer Management and Research, 2019, Volume 11, 9899-9905.	1.9	7
18	Less circulating mucosal-associated invariant T cells in patients with cervical cancer. Taiwanese Journal of Obstetrics and Gynecology, 2019, 58, 117-121.	1.3	14

CHIH-LONG CHANG

#	Article	IF	CITATIONS
19	Antitumor effects of BMS-777607 on ovarian cancer cells with constitutively activated c-MET. Taiwanese Journal of Obstetrics and Gynecology, 2019, 58, 145-152.	1.3	7
20	Clinical significance of c-Met and phospho-c-Met (Tyr1234/1235) in ovarian cancer. Taiwanese Journal of Obstetrics and Gynecology, 2019, 58, 105-110.	1.3	6
21	Impact of para-aortic recurrence risk-guided intensity-modulated radiotherapy in locally advanced cervical cancer with positive pelvic lymph nodes. Gynecologic Oncology, 2018, 148, 291-298.	1.4	45
22	The Effect of Body Mass Index and Weight Change on Late Gastrointestinal Toxicity in Locally Advanced Cervical Cancer Treated With Intensity-modulated Radiotherapy. International Journal of Gynecological Cancer, 2018, 28, 1377-1386.	2.5	17
23	Skeletal Muscle Loss Is an Imaging Biomarker of Outcome after Definitive Chemoradiotherapy for Locally Advanced Cervical Cancer. Clinical Cancer Research, 2018, 24, 5028-5036.	7.0	58
24	Prophylactic lower para-aortic irradiation using intensity-modulated radiotherapy mitigates the risk of para-aortic recurrence in locally advanced cervical cancer: A 10-year institutional experience. Gynecologic Oncology, 2017, 146, 20-26.	1.4	32
25	Safety and efficacy of semiextended field intensity-modulated radiation therapy and concurrent cisplatin in locally advanced cervical cancer patients. Medicine (United States), 2017, 96, e6158.	1.0	21
26	Malignant transformation of ovarian mature cystic teratoma into squamous cell carcinoma: a Taiwanese Gynecologic Oncology Group (TGOG) study. Journal of Gynecologic Oncology, 2017, 28, e69.	2.2	40
27	Enhanced anti-tumor therapeutic efficacy of DNA vaccine by fusing the E7 gene to BAFF in treating human papillomavirus-associated cancer. Oncotarget, 2017, 8, 33024-33036.	1.8	10
28	The air matters – sleeve air cavity as a marker guiding image-guided helical tomotherapy to target cervical cancer. Journal of Contemporary Brachytherapy, 2016, 1, 82-87.	0.9	5
29	Possible surrogate marker for an effective dose-dense chemotherapy in treating ovarian cancer. Taiwanese Journal of Obstetrics and Gynecology, 2016, 55, 405-409.	1.3	10
30	Paraneoplastic cerebellar degeneration in a patient with ovarian cancer. Taiwanese Journal of Obstetrics and Gynecology, 2015, 54, 313-315.	1.3	7
31	Nanoparticle-induced intraperitoneal hyperthermia and targeted photoablation in treating ovarian cancer. Oncotarget, 2015, 6, 26861-26875.	1.8	21
32	Dose-Dense Chemotherapy Improves Mechanisms of Antitumor Immune Response. Cancer Research, 2013, 73, 119-127.	0.9	138
33	Survival analysis of Stage IIA1 and IIA2 cervical cancer patients. Taiwanese Journal of Obstetrics and Gynecology, 2013, 52, 33-38.	1.3	13
34	ls conization once following by simple hysterectomy sufficient for all clinical stage IA1 cervical squamous cell carcinoma?. Taiwanese Journal of Obstetrics and Gynecology, 2013, 52, 385-388.	1.3	4
35	Intra-Peritoneal Hyperthermia Combining α-Galactosylceramide in the Treatment of Ovarian Cancer. PLoS ONE, 2013, 8, e69336.	2.5	5
36	Immune Mechanism of the Antitumor Effects Generated by Bortezomib. Journal of Immunology, 2012, 189, 3209-3220.	0.8	71

CHIH-LONG CHANG

#	Article	IF	CITATIONS
37	Role of Transperitoneal Laparoscopic Para-aortic Lymph Node Dissection for the Treatment of Elderly Patients with Locally Advanced Squamous Cell Carcinoma of the Uterine Cervix. International Journal of Gerontology, 2012, 6, 206-210.	0.6	0
38	Rapid aneuploidy diagnosis by multiplex ligation-dependent probe amplification using uncultured amniocytes in pregnancy with major fetal structural abnormalities. Taiwanese Journal of Obstetrics and Gynecology, 2012, 51, 123-128.	1.3	7
39	Extending platinum-free interval in partially platinum-sensitive recurrent ovarian cancer by a non-platinum regimen: Its possible clinical significance. Taiwanese Journal of Obstetrics and Gynecology, 2012, 51, 336-341.	1.3	18
40	Brain metastases from epithelial ovarian carcinoma: Evaluation of prognosis and managements — A Taiwanese Gynecologic Oncology Group (TGOG) Study. Gynecologic Oncology, 2012, 125, 37-41.	1.4	16
41	Rapid aneuploidy diagnosis by multiplex ligation-dependent probe amplification and array comparative genomic hybridization in pregnancy with major congenital malformations. Taiwanese Journal of Obstetrics and Gynecology, 2011, 50, 85-94.	1.3	24
42	Stress-induced Phosphoprotein 1 as a Secreted Biomarker for Human Ovarian Cancer Promotes Cancer Cell Proliferation. Molecular and Cellular Proteomics, 2010, 9, 1873-1884.	3.8	98
43	Treatment With Cyclooxygenase-2 Inhibitors Enables Repeated Administration of Vaccinia Virus for Control of Ovarian Cancer. Molecular Therapy, 2009, 17, 1365-1372.	8.2	43
44	Inactivation of viruses with a femtosecond laser via impulsive stimulated Raman scattering. , 2008, , .		6
45	Inactivation of viruses by laser-driven coherent excitations via impulsive stimulated Raman scattering process. Journal of Biomedical Optics, 2007, 12, 064030.	2.6	30
46	Cancer Immunotherapy Using Irradiated Tumor Cells Secreting Heat Shock Protein 70. Cancer Research, 2007, 67, 10047-10057.	0.9	26
47	Retinoic acid-induced glandular differentiation of the oesophagus. Gut, 2007, 56, 906-917.	12.1	55
48	Inactivation of viruses with a very low power visible femtosecond laser. Journal of Physics Condensed Matter, 2007, 19, 322102.	1.8	32
49	Inactivation of viruses by coherent excitations with a low power visible femtosecond laser. Virology Journal, 2007, 4, 50.	3.4	48
50	Modified Wheelahan's Colposuspension in the Treatment of Genuine Stress Incontinence. Journal of Gynecologic Surgery, 2002, 18, 59-64.	0.1	0
51	Prenatal diagnosis and genetic analysis of X chromosome polysomy 49,XXXXY. Prenatal Diagnosis, 2000, 20, 754-757.	2.3	21
52	Modified Radical Hysterectomy for Early Ib Cervical Cancer. Gynecologic Oncology, 1999, 74, 241-244.	1.4	47